Repligen Corp at KeyBanc Capital Markets Life Sciences & Medtech Investor Forum (virtual) Transcript
Good morning. This is Paul Knight, the analyst at KeyBanc covering Repligen in the life science industry. Welcome to the Repligen fireside chat. We have Tony Hunt, CEO of Repligen; Jon Snodgres, the CFO; Sondra Newman of Investor Relations; and Steve Chehames in Investor Relations as well.
The format will be just a brief overview from Tony on the business, and then we'll -- I'll run some Q&A. But for people who are online, there's a section at the bottom of your screen where you may submit questions. I'll take those questions and ask management what you're asking.
And with that, Tony, I'll let you begin.
Great. Thanks, Paul, and Jon and myself will tag team today. Yes, maybe the best way to kind of talk about where the company is, maybe highlight what's happened over the last year, we obviously had a great year in 2020, up 36%.
Half of our growth came from -- that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |